Biotech & Medical Venture Deals Roundup
From BioHealth Investor by Adam Rubenstein NeoVista, Inc. (Fremont, CA), an ophthalmic device company focused on the treatment of age-related macular degeneration, has raised $41M in Series C funding. Essex Woodlands Health Ventures led the deal along with MPM Capital…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
From BioHealth Investor
NeoVista, Inc. (Fremont, CA), an ophthalmic device company focused on the treatment of age-related macular degeneration, has raised $41M in Series C funding. Essex Woodlands Health Ventures led the deal along with MPM Capital and previous investors SV Life Sciences, Versant Ventures, The Carlyle Group and Accuitive Medical Ventures.
Quinnova Pharmaceuticals, Inc., a specialty dermatological reformulation pharmaceutical company focused on innovative dermal drug delivery platforms, has completed a $13.6M Series A round of financing. Participating in the round are Thomas, McNerney & Partners, H.I.G. Ventures and an investor syndicate led by Omnivest (Bermuda) Ltd.
Ampla Pharmaceuticals, Inc. (La Jolla, CA) has raised $5.47M in Series A funding. Still operating in stealth mode the company website is currently unavailable. Investors include Integra Ventures, Advent International and Crabtree Ventures
Aushon BioSystems (Burlington, MA), which provides microarray-based tools, instrumentation and services for life science research, drug discovery/development and clinical diagnostics, announced they have closed their Series A $7.78M financing. North Bridge Venture Partners led the deal.
http://www.biohealthinvestor.com/
Contact [email protected] for any questions or corrections.
Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.
McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.
His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.
A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.
TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.
McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.
